Samanta Vencappa
Cisplatin induced sensory neuropathy is prevented by vascular endothelial growth factor-A
Vencappa, Samanta; Donaldson, Lucy F.; Hulse, Richard P.
Authors
Lucy F. Donaldson
Richard P. Hulse
Abstract
Increased patient survival is a mark of modern anti-cancer therapy success. Unfortunately treatment side-effects such as neurotoxicity are a major long term concern. Sensory neuropathy is one of the common toxicities that can arise during platinum based chemotherapy. In many cases the current poor understanding of the neurological degeneration and lack of suitable analgesia has led to high incidences of patient drop out of treatment. VEGF-A is a prominent neuroprotective agent thus it was hypothesised to prevent cisplatin induced neuropathy. Systemic cisplatin treatment (lasting 3 weeks biweekly) resulted in mechanical allodynia and heat hyperalgesia in mice when compared to vehicle control. PGP9.5 sensory nerve fibre innervation was reduced in the plantar skin in the cisplatin treated group versus vehicle control mice. The cisplatin induced sensory neurodegeneration was associated with increased cleaved caspase 3 expression as well as a reduction in Activating Transcription Factor 3 and panVEGF-A expression in sensory neurons. VEGF-A165b expression was unaltered between vehicle and cisplatin treatment. rhVEGF-A165a and rhVEGF-A165b both prevented cisplatin induced sensory neurodegeneration. Cisplatin exposure blunts the regenerative properties of sensory neurons thus leading to sensory neuropathy. However, here it is identified that administration of VEGF-A isoform subtypes induce regeneration and prevent cell death and are therefore a possible adjunct therapy for chemotherapy induced neuropathy.
Citation
Vencappa, S., Donaldson, L. F., & Hulse, R. P. (2015). Cisplatin induced sensory neuropathy is prevented by vascular endothelial growth factor-A. American Journal of Translational Research, 7(6),
Journal Article Type | Article |
---|---|
Acceptance Date | Jun 13, 2015 |
Online Publication Date | Jun 15, 2015 |
Publication Date | Jun 30, 2015 |
Deposit Date | Mar 21, 2018 |
Publicly Available Date | Mar 21, 2018 |
Journal | American Journal of Translational Research |
Electronic ISSN | 1943-8141 |
Publisher | e-Century Publishing |
Peer Reviewed | Peer Reviewed |
Volume | 7 |
Issue | 6 |
Public URL | https://nottingham-repository.worktribe.com/output/753544 |
Publisher URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532737/ |
Contract Date | Mar 21, 2018 |
Files
VEGF Cisplatin AJTR final accepted version.pdf
(889 Kb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search